Shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) traded up 5.9% during mid-day trading on Tuesday following insider buying activity. The stock traded as high as $6.97 and last traded at $6.80. 5,631,313 shares were traded during trading, an increase of 94% from the average session volume of 2,902,519 shares. The stock had previously closed at $6.42.

Specifically, Director Tommy G. Thompson purchased 5,000 shares of the stock in a transaction dated Friday, December 8th. The shares were purchased at an average price of $6.21 per share, with a total value of $31,050.00. Following the transaction, the director now owns 3,555 shares in the company, valued at approximately $22,076.55. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 23.92% of the company’s stock.

Several analysts recently issued reports on TXMD shares. Oppenheimer set a $10.00 price objective on shares of TherapeuticsMD and gave the company a “buy” rating in a report on Thursday, August 17th. BidaskClub upgraded shares of TherapeuticsMD from a “strong sell” rating to a “sell” rating in a report on Tuesday. Morgan Stanley started coverage on shares of TherapeuticsMD in a report on Friday, September 8th. They issued an “equal weight” rating and a $6.00 price objective on the stock. Noble Financial restated a “buy” rating on shares of TherapeuticsMD in a report on Thursday, November 30th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $20.00 price objective on shares of TherapeuticsMD in a report on Monday, August 21st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the stock. TherapeuticsMD presently has an average rating of “Buy” and a consensus target price of $15.00.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings data on Monday, November 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.03. The firm had revenue of $4.42 million for the quarter, compared to analyst estimates of $5.36 million. TherapeuticsMD had a negative net margin of 457.00% and a negative return on equity of 65.16%. TherapeuticsMD’s revenue was down 19.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.13) EPS. research analysts predict that TherapeuticsMD, Inc. will post -0.37 earnings per share for the current year.

A number of large investors have recently modified their holdings of TXMD. Amalgamated Bank increased its stake in TherapeuticsMD by 7.2% during the second quarter. Amalgamated Bank now owns 19,744 shares of the company’s stock worth $104,000 after purchasing an additional 1,322 shares during the period. Principal Financial Group Inc. increased its stake in TherapeuticsMD by 3.9% during the second quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock worth $114,000 after purchasing an additional 818 shares during the period. Virtu KCG Holdings LLC purchased a new stake in TherapeuticsMD during the second quarter worth about $157,000. Quantbot Technologies LP purchased a new stake in TherapeuticsMD during the third quarter worth about $189,000. Finally, Cetera Investment Advisers purchased a new stake in TherapeuticsMD during the second quarter worth about $214,000. Institutional investors own 73.76% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “TherapeuticsMD (TXMD) Trading 5.9% Higher on Insider Buying Activity” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/12/therapeuticsmd-txmd-trading-5-9-higher-on-insider-buying-activity.html.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Receive News & Stock Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related stocks with our FREE daily email newsletter.